Spine fusion for Mesoblast

By Dylan Bushell-Embling
Thursday, 21 August, 2008

Preclinical trials of Mesoblast’s [ASX: MSB] allogenic stem cells for cervical spine fusion have been very promising.

Use of the company's stem cells has been shown to be an effective and safe method of interbody fusion of the cervical spine in the neck, the company said.

The results come after an announcement by the US FDA that the current leading treatment, recombinant human Bone Morphogenetic Protein [rhBMP], can cause life threatening complications when used in the cervical spine.

According to the FDA, rhBMP, when used for cervical fusion, can cause swelling of the neck and throat tissue, which can result in compression of the airway and neurological structures in the neck.

Fusion of the cervical spine accounts for up to 40 per cent of all spinal fusion procedures.

Related News

Protein-based therapy helps the body remove harmful cells

Scientists have created a protein-based therapeutic tool that could change the way we treat...

Diabetes changes the structure of our hearts, study finds

Type 2 diabetes directly alters the heart's structure and energy systems, which explains why...

Beta blockers could halt triple negative breast cancer

Researchers have identified a molecular biomarker in triple negative breast cancer tumours which...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd